Navigation Links
Oncolytics Biotech(R) Inc. To Host Conference Call to Discuss Updated U.K. Phase I/II Trial Head and Neck Cancer Data Being Presented at the ASCO Annual Meeting
Date:6/4/2010

CALGARY, June 4 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that Dr. Brad Thompson, President and CEO, will host a conference call and webcast on Monday, June 7th, 2010 at 7:00 a.m. MT (9:00 a.m. ET) to discuss the Phase I/II head and neck cancer data being presented that day at the ASCO Annual Meeting in Chicago, IL.

To access the conference call by telephone, dial 1-647-427-7450 or 1-888-231-8191. A live audio webcast will also be available at the following link: http://www.newswire.ca/en/webcast/viewEvent.cgi?eventID=3108600 or through the Company's website at www.oncolyticsbiotech.com. Please connect at least 15 minutes prior to the webcast to ensure adequate time for any software download that may be needed. A replay of the webcast will be available at www.oncolyticsbiotech.com and will also be available by telephone through June 14th, 2010. To access the telephone replay, dial 1-416-849-0833 or 1-800-642-1687 and enter reservation number 80060184 followed by the number sign.

About Oncolytics Biotech Inc.

Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of human trials including a Phase III trial in head and neck cancers using REOLYSIN, its proprietary formulation of the human reovirus. For further information about Oncolytics, please visit: www.oncolyticsbiotech.com.

The presentation time is subject to change. This press release and the presentations related thereto contain forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including the timing, implication and accuracy of materials presented at the ASCO meeting with respect to REOLYSIN, and the Company's belief as to the potential of REOLYSIN as a cancer therapeutic, involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the efficacy of REOLYSIN as a cancer treatment, the tolerability of REOLYSIN outside a controlled test, the success and timely completion of clinical studies and trials, the Company's ability to successfully commercialize REOLYSIN, uncertainties related to the research and development of pharmaceuticals and uncertainties related to the regulatory process. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned against placing undue reliance on forward-looking statements. The Company does not undertake to update these forward-looking statements, except as required by applicable laws.


'/>"/>
SOURCE Oncolytics Biotech Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Oncolytics Biotech(R) Inc. Receives Approval from Belgium FAMHP to Conduct Phase 3 Trial for REOLYSIN(R) in Head and Neck Cancers
2. Oncolytics Biotech(R) Inc. Announces Start of Enrolment in U.S. Phase 2 Pancreatic Cancer Clinical Trial
3. Oncolytics Biotech(R) Inc. Announces Opening of Enrollment in Phase 3 Trial for REOLYSIN(R) in Head and Neck Cancers
4. Oncolytics Biotech(R) Inc. Announces Reovirus Research to be Presented at ASCO Annual Meeting
5. Oncolytics Biotech(R) Inc. Announces Phase I Colorectal Cancer Study
6. Oncolytics Biotech(R) Inc. Announces Publication of Phase I Clinical Trial Results in Clinical Cancer Research
7. Oncolytics Biotech(R) Inc. Announces First Quarter 2010 Results
8. Oncolytics Biotech(R) Inc. Announces Details of 2010 Annual Shareholder Meeting
9. Oncolytics Biotech(R) Inc. Completes Patient Enrollment in Phase I Portion of U.S. Phase I/II Recurrent Malignant Gliomas Clinical Trial
10. Oncolytics Biotech(R) Inc. Receives Approval from the U.K. MHRA to Conduct Phase 3 Trial for REOLYSIN(R) in Head and Neck Cancers
11. Oncolytics Biotech(R) Inc. Appoints Senior Vice President, Global Licensing and Business Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... ... February 09, 2016 , ... With a presidential election in November and the ... will bring together over 500 top healthcare leaders for a night and day of ... organized by MBA students of the University of Pennsylvania’s Wharton School, will be held ...
(Date:2/9/2016)... of Prussia, PA (PRWEB) , ... February 09, 2016 , ... ... Business Development, Europe. Based in Paris, he will focus on acquiring new accounts ... are being met. , “Fred brings to our European clients more ...
(Date:2/9/2016)... 2016 This market research report on the ... prospects of the market in terms of revenue (USD ... in the manufacture of microbiology culture media and related ... market snapshot providing the overall information of various market ... section also provides the overall information and data analysis ...
(Date:2/8/2016)... - BIOREM Inc. (TSXV: BRM) ("Biorem" or "the Company") today ... technology companies in the TSX Venture 50 TM . ... the TSX Venture Exchange, in each of five major industry ... & life sciences, diversified industries and technology – based on ... investment, market cap growth, trading volume and analyst coverage. All ...
Breaking Biology Technology:
(Date:2/3/2016)... Vigilant Solutions announces today that the ... Missouri solved two recent hit-and-run cases with ... Vigilant Solutions. Brian Wenberg explains, "I ... was walking out of a convenience store and witnessed an elderly male back ... striking his vehicle and leaving the scene.  In his ...
(Date:2/2/2016)... , Feb. 2, 2016 Checkpoint Inhibitors ... Rising Market Are you interested in the ... revenues for checkpoint inhibitors. Visiongain,s report gives those ... product and national level. Avoid falling behind ... progress, opportunities and revenues those emerging cancer therapies ...
(Date:2/1/2016)... 2016 Rising sales of consumer ... touchfree intuitive gesture control market size ... of consumer electronics coupled with new technological advancements to ... size through 2020   --> ... technological advancements to drive global touchfree intuitive gesture control ...
Breaking Biology News(10 mins):